Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Yang, James Chih-Hsin Hirsh, Vera Schuler, Martin Yamamoto, Nobuyuki O'Byrne, Kenneth J Mok, Tony S K Zazulina, Victoria Shahidi, Mehdi Lungershausen, Juliane Massey, Dan
Yang, James Chih-Hsin
Hirsh, Vera
Schuler, Martin
Yamamoto, Nobuyuki
O'Byrne, Kenneth J
Mok, Tony S K
Zazulina, Victoria
Shahidi, Mehdi
Lungershausen, Juliane
Massey, Dan
An error occurred retrieving the object's statistics
Advisors
Editors
Other Contributors
Departments
James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Martin Schuler, West German Cancer Center, University Duisburg-Essen, Essen; Juliane Lungershausen, Boehringer Ingelheim GmbH, Ingelheim, Germany; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; Kenneth J. O'Byrne, St James' Hospital, Dublin, Ireland; Tony S.K. Mok, State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong; Victoria Zazulina, Mehdi Shahidi, and Dan Massey, Boehringer Ingelheim Limited, Bracknell; Michael Palmer, Keele University, Keele, United Kingdom; and Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Date
2013-09-20
Date Submitted
Keywords
LUNG CANCER
QUALITY OF LIFE
QUALITY OF LIFE
Other Subjects
Subject Mesh
Adenocarcinoma
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Glutamates
Guanine
Humans
Lung Neoplasms
Mutation
Neoplasm Staging
Quality of Life
Quinazolines
Receptor, Epidermal Growth Factor
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Glutamates
Guanine
Humans
Lung Neoplasms
Mutation
Neoplasm Staging
Quality of Life
Quinazolines
Receptor, Epidermal Growth Factor
Treatment Outcome
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed.
Language
en
ISSN
1527-7755
eISSN
ISBN
DOI
10.1200/JCO.2012.46.1764
PMID
23816967